Date Time
Women’s stronger immune response could protect from some skin cancers
Women may have a stronger immune response to a common form of skin cancer than men, according to early research on mice and human cells.
Led by University of Manchester scientists at the Cancer Research UK Manchester Institute, the team publish their findings in Clinical Cancer Research.
The study is funded by The Wellcome Trust, Cancer Research UK and the Royal Society.
Men have more skin squamous cell carcinoma (cSCC) than females and their tumours are more aggressive. It is not clear if this is linked to more exposure to sunlight. This study used animals to explore this question.
Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body s phagocytes and facilitates extensive activation of the immune system.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers reveal how different therapies impact the surrounding immune environment of metastatic melanoma tumors according to location and identify a rare population of immune cells that is associated with improved overall survival.
Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti
June 01, 2021 08:00 ET | Source: Immutep Limited Immutep Limited
Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfa
New investigator-initiated explorative, multi-centre, open-labelled Phase I/IIa trial in 12 previously treated patients with different solid tumours, called INSIGHT-005
First patient is expected to be enrolled and dosed in H2 of calendar year 2021
SYDNEY, AUSTRALIA , June 01, 2021 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announces a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany for a Phase I/IIa clinical trial in patients with solid tumours, called INSIGHT-005.